Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SL-279252

Fusion protein · Agonist of OX40 (TNFRSF4) and PD-1 (PDCD1) · developed by Shattuck Labs

Phase 1 Most advanced trial (none active)
STTK Developer
1 Registered trials

What is SL-279252?

SL-279252 is an agonist redirected checkpoint fusion protein built from the extracellular domains of PD-1 and OX40 ligand joined by an Fc domain. It binds PD-1 and OX40 on T-lymphocytes at the same time, aiming to stimulate OX40 while blocking PD-1 signaling. It is being studied in several solid tumors and lymphomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Fusion protein
Targets
OX40 (TNFRSF4), PD-1 (PDCD1)
Mechanism
Agonist of OX40 (TNFRSF4) and PD-1 (PDCD1)
Pathways
T-cell co-stimulation, PD-1 signaling inhibition, T-cell proliferation and cytokine production
Therapy area
Oncology
Developer
Shattuck Labs, Inc. (STTK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03894618 Phase 1 Squamous Cell Carcinoma of the Head and Neck Completed STTK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Large B Cell LymphomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaHodgkin LymphomaMelanomaMismatch Repair Deficient or MSI-High Solid TumorsNon Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the SkinUrothelial Carcinoma

Other drugs acting on TNFRSF4 / PDCD1

More from Shattuck Labs

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the STTK page.

Follow STTK, the company behind SL-279252

See STTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

STTK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.